Page last updated: 2024-11-10

z 338

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Z 338: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9957090
SCHEMBL ID6968566
MeSH IDM0366361

Synonyms (37)

Synonym
n-(n',n'-diisopropylaminoethyl)-(2-(2-hydroxy-4,5-dimethoxybenzoylamino)-1,3-thiazole-4-yl)carboxyamide
acotiamide hydrochloride
z 338
185104-11-4
4-thiazolecarboxamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-((2-hydroxy-4,5-dimethoxybenzoyl)amino)-, monohydrochloride
unii-510791nn30
z338
510791nn30 ,
acotiamide hydrochloride anhydrous
acotiamide hydrochloride [mi]
4-thiazolecarboxamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-((2-hydroxy-4,5-dimethoxybenzoyl)amino)-, hydrochloride (1:1)
acotiamide hydrochloride [who-dd]
SCHEMBL6968566
acotiamide hcl
DTXSID30171717
AKOS030529148
n-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-4-thiazolecarboxamide hydrochloride
mfcd23103502
J-011862
acotiamide dihydrochloride, >=98% (hplc)
n-(2-(diisopropylamino)ethyl)-2-(2-hydroxy-4,5-dimethoxybenzamido)thiazole-4-carboxamide hydrochloride
n-[2-(diisopropylamino)ethyl]-2-(2-hydroxy-4,5-dimethoxybenzamido)thiazole-4-carboxamide hydrochloride
SY226332
VQEKQYLTAIVCBW-UHFFFAOYSA-N
DS-19577
acotiamide dihydrochloride
z-338 dihydrochloride
acotiamidehydrochloride
SB19647
n-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;hydrochloride
Q27260838
n-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-4-thiazolecarboxamide
F14757
HY-121467A
CS-0103547
acotiamide (hydrochloride)
n-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-hydroxy-4,5-dimethoxybenzamido)-1,3-thiazole-4-carboxamide hydrochloride

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The incidence rate of adverse drug reactions was 11."( A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
Akiho, H; Hongo, M; Matsueda, K; Ushijima, S, 2011
)
0.37
" Adverse events were not significantly different between acotiamide and placebo groups."( Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
Deng, J; Fan, J; Guo, Q; Tan, S; Wan, C; Xiao, G; Xie, X; Zhu, Y, 2014
)
0.4
"Acotiamide has the potential to improve the symptoms of patients with FD, particularly of patients with PDS, without major adverse effects."( Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
Deng, J; Fan, J; Guo, Q; Tan, S; Wan, C; Xiao, G; Xie, X; Zhu, Y, 2014
)
0.4
" No specific clinically significant safety concerns have been shown, with no deaths, treatment-related severe/serious adverse events, or any clinically significant laboratory test results."( Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
Banciu, C; Bunganic, I; Eavis, P; Kleban, Y; Miyagawa, T; Pokrotnieks, J; Tack, J; Törnblom, H; Tsuchikawa, M; Urbonas, G; Yakusevich, V, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" Thus the present ultra-high-pressure liquid chromatograhy-high-resolution mass spectrometry method for determination of ACT in rat plasma, is highly sensitive and rapid with a short run-time of 4 min, can be suitable for high sample throughput and for large batches of biological samples in pharmacokinetic studies."( Quantitation of acotiamide in rat plasma by UHPLC-Q-TOF-MS: method development, validation and application to pharmacokinetics.
Gananadhamu, S; Kalariya, PD; Patel, PN; Srinivas, R; Swamy, CV, 2016
)
0.43
"Concentration profiles of acotiamide and acetylcholine (ACh) were determined after intravenous administration to rats and analyzed by physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model containing vascular space, precursor pool and deep pool of stomach."( Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach.
Hirayama, M; Iikura, M; Kawabata, Y; Toda, R; Yoshii, K, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"In the present study, the inhibitory properties of N-[2-(diisopropylamino)ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide monohydrochloride trihydrate (Z-338), a novel gastroprokinetic agent, were investigated and compared with those of cisapride to establish its potential for drug-drug interactions."( Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.
Furuta, S; Kamada, E; Kawabata, Y; Kurimoto, T; Omata, T; Sugimoto, T; Wu, XC; Yonezawa, K, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" The oral absolute bioavailability (F) of acotiamide in rats was estimated to be 38."( Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma.
Huang, R; Li, J; Qu, H; Sun, M; Wang, Z; Zhao, Z, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
"The present two studies were conducted to examine the optimal dosage of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia (FD) in Japan."( Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
Aoki, H; Hongo, M; Kato, H; Matsueda, K; Saito, Y; Tack, J, 2010
)
0.36
" The dosage of acotiamide 100 mg tid might be the appropriate dose in the treatment of FD."( Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
Deng, J; Fan, J; Guo, Q; Tan, S; Wan, C; Xiao, G; Xie, X; Zhu, Y, 2014
)
0.4
" The proposed method has been successfully applied to the analysis of the drug in its new pharmaceutical dosage form and the results have been statistically compared with the reported HPLC method showing no significant differences by applying t-test and F-test."( Spectrofluorimetric determination of acotiamide hydrochloride trihydrate in the presence of its oxidative degradation product.
Attia, KAM; El-Olemy, A; Nassar, MWI; Ramzy, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (13.16)29.6817
2010's54 (71.05)24.3611
2020's12 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (22.37%)5.53%
Reviews13 (17.11%)6.00%
Case Studies2 (2.63%)4.05%
Observational3 (3.95%)0.25%
Other41 (53.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia [NCT01973790]Phase 3207 participants (Actual)Interventional2014-03-31Completed
To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms [NCT00761358]Phase 3820 participants (Anticipated)Interventional2008-09-30Completed
A Phase 1, Randomized, Double-Blind, Placebo- and Active- Controlled, Crossover Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Male and Female Adult Subjects [NCT00850746]Phase 180 participants (Actual)Interventional2009-02-28Completed
Z-338 Phase III Trial - Evaluation of Pharmacokinetics, Efficacy and Safety in Paediatric Patients With Functional Dyspepsia [NCT04526119]Phase 3100 participants (Anticipated)Interventional2021-02-22Recruiting
A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia [NCT00764374]Phase 3412 participants (Actual)Interventional2008-08-31Completed
A Pharmacokinetics Study to Evaluate the Effect of Food Intake on PK Profile of Z-338 in Healthy Volunteers [NCT00920998]Phase 130 participants (Actual)Interventional2009-03-31Completed
Acotiamide Affects Antral Motility, But Has no Effect on Fundic Motility, Gastric Emptying or Symptom Perception in Healthy Participants [NCT03402984]20 participants (Actual)Interventional2017-04-01Completed
[NCT00323817]Phase 2282 participants (Anticipated)Interventional2006-04-30Completed
Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial [NCT04697641]202 participants (Actual)Interventional2017-09-01Completed
The Effect of Z-338 in Subjects With Functional Dyspepsia, Evaluate the Function of Gastro-duodenum by Ultrasound [NCT00458328]Phase 240 participants (Anticipated)Interventional2007-04-30Completed
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia [NCT00102310]Phase 2416 participants (Actual)Interventional2004-03-10Completed
The Effects of Z-338 on the Symptomatic Response to a Nutrient Challenge and Gastric Nutrient Distribution and Emptying in Subjects With and Without Functional Dyspepsia [NCT00298194]Phase 252 participants (Anticipated)Interventional2006-02-28Completed
To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms [NCT00333372]Phase 2440 participants Interventional2006-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]